38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – October 26-28, 2022
The following summarizes some of the highlights from Day 1 of ECTRIMS 2022.
Latest News
Re-evaluating the benefit-risk of high-efficacy treatment in MS
October 3, 2022Click here to take the survey on HE Benefit-risk
The management of multiple sclerosis has begun to shift away from the traditional escalation model – intensifying therapy in response to ongoing disease activity or progression – to one in which high-efficacy DMTs are used earlier in the clinical course. Read More
Bivalent COVID booster approved in Canada
September 16, 2022In September, Health Canada approved the use of a first-generation bivalent booster vaccine against the SARS CoV-2 virus for use in adults aged >18 years (www.canada.ca/en/health-canada/news/2022/09/health-canada-authorizes-first-bivalent-covid-19-booster-for-adults-18-years-and-older.html). Read More
Three biomarkers of DMT adverse effects proposed
August 25, 2022A new review has summarized three potential biomarkers of adverse effects that may occur with disease-modifying therapies used in the treatment of MS (Kreft et al. J Neurol 2022;269:5192-5193). (Free references below.) All results are preliminary and further validation is required.